Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.

被引：0
|
作者：
Cazzaniga, Marina Elena
Pronzato, Paolo
Schettini, Francesco
Del Mastro, Lucia
Riemma, Maria
Alu, Massimiliano
Turletti, Anna
Giordano, Monica
Pugliese, Palma
De Angelis, Claudia
Garrone, Ornella
Marchetti, Paolo
Riccardi, Ferdinando
Bernardo, Antonio
Livi, Lorenzo
Fabi, Alessandra
Taverniti, Cristiana
De Placido, Sabino
Mustacchi, Giorgio
机构：
[1] ASST Monza, Phase Res Unit 1, Monza, Italy
[2] San Martino IST Ist Naz Ric Cancro, Genoa, Italy
[3] Univ Naples Federico II, Naples, Italy
[4] Natl Canc Inst, IRCCS AOU San Martino IST, Dept Med Oncol, Genoa, Italy
[5] Ist Nazl Tumori IRCCS, Fdn G Pascale, Breast Oncol Unit, Naples, Italy
[6] ARNAS Civ, Med Oncol Unit, Palermo, Italy
[7] ASLTO1 Osped Martini, Med Oncol, Turin, Italy
[8] Santa Anna Hosp, Como, Italy
[9] AOS Anna UO Oncol Med, Como, Italy
[10] Osped S Chiara, ITT, AOU Pisana, Med Oncol, Pisa, Italy
[11] S Croce & Carle Teaching Hosp, Breast Unit Med Oncol, Cuneo, Italy
[12] St Andrea Univ Hosp, Dept Med Oncol, Rome, Italy
[13] Cardarelli Hosp, Breast Unit, Naples, Italy
[14] Fdn Maugeri IRCCS, Pavia, Italy
[15] Univ Florence, Florence, Italy
[16] Regina Elena Inst Canc Res, Div Med Oncol, Rome, Italy
[17] AOU Citta Salute & Sci, Med Oncol, Turin, Italy
[18] Univ Federico II Naples, Dept Clin Med & Surg, Oncol Unit, Naples, Italy
[19] Univ Trieste, Trieste, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e12528
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e12528
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) in MONALEESA(ML)-2.
    Hart, Lowell L.
    Bardia, Aditya
    Beck, Joseph Thaddeus
    Chan, Arlene
    Neven, Patrick
    Hamilton, Erika P.
    Sohn, Joohyuk
    Sonke, Gabe S.
    Bachelot, Thomas
    Spring, Laura
    Le Gac, Fabienne
    Hu, Huilin
    Gao, Ming
    De laurentiis, Michelino
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [32] Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab
    Michel, Laura L.
    Hartkopf, Andreas D.
    Fasching, Peter A.
    Kolberg, Hans-Christian
    Hadji, Peyman
    Tesch, Hans
    Haberle, Lothar
    Ettl, Johannes
    Luftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Beckmann, Matthias W.
    Belleville, Erik
    Volz, Bernhard
    Huebner, Hanna
    Wimberger, Pauline
    Hielscher, Carsten
    Mundhenke, Christoph
    Kurbacher, Christian
    Wuerstlein, Rachel
    Untch, Michael
    Overkamp, Friedrich
    Huober, Jens
    Janni, Wolfgang
    Taran, Florin-Andrei
    Lux, Michael P.
    Wallwiener, Diethelm
    Brucker, Sara Y.
    Schneeweiss, Andreas
    Fehm, Tanja N.
    CANCERS, 2020, 12 (10) : 1 - 15
  • [33] Progression-free survival (PFS) by independent review and updated overall survival (OS) results from Alliance A031203 trial (CABOSUN): Cabozantinib versus sunitinib as initial targeted therapy for patients (pts) with metastatic renal cell carcinoma (mRCC)
    Choueiri, T. K.
    Hessel, C.
    Halabi, S.
    Sanford, B.
    Hahn, O.
    Michaelson, M. D.
    Walsh, M.
    Olencki, T.
    Picus, J.
    Small, E. J.
    Dakhil, S.
    Scheffold, C.
    George, D. J.
    Morris, M. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [34] Phase II study of weekly paclitaxel with trastuzumab and pertuzumab in patients with HER2-overexpressing metastatic breast cancer (MBC): Updated progression-free survival with overall survival result
    Smyth, Lillian Mary
    Iyengar, Neil M.
    Chandarlapaty, Sarat
    Sugarman, Steven
    Comen, Elizabeth Anne
    Drullinsky, Pamela
    Sklarin, Nancy T.
    Traina, Tiffany A.
    Troso-Sandoval, Tiffany A.
    Patil, Sujata
    Wasserheit-Lieblich, Carolyn
    Argolo, Daniel Fontes Santos De Teive E.
    Baselga, Jose
    Norton, Larry
    Hudis, Clifford A.
    Dang, Chau T.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Overall Survival (OS) and Progression-Free Survival (PFS) in Patients Treated with Fedratinib as First-Line Myelofibrosis (MF) Therapy and after Prior Ruxolitinib (RUX): Results from the JAKARTA and JAKARTA2 Trials
    Harrison, Claire
    Kiladjian, Jean-Jacques
    Verstovsek, Srdan
    Vannucchi, Alessandro
    Mesa, Ruben
    Reiter, Andreas
    Zhang, Jun
    Rose, Shelonitda
    Mascarenhas, John
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S356 - S356
  • [36] Impact of ribociclib (RIB) dose reduction on overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) in MONALEESA (ML)-3 and-7
    De Laurentiis, M.
    Merino, L. de la Cruz
    Hart, L.
    Bardia, A.
    Im, S-A.
    Sohn, J.
    Neven, P.
    Martin, M.
    Ji, Y.
    Yang, S.
    Hu, H.
    Lteif, A.
    Tripathy, D.
    ANNALS OF ONCOLOGY, 2020, 31 : S378 - S379
  • [37] Prognostic value of neutrophil-to-lymphocyte ratio (NLR) on overall survival (OS), progression free survival (PFS) and disease control rate (DCR) in patients with metastatic colorectal cancer (mCRC) from the RECOURSE study.
    Argiles, Guillem
    Yoshino, Takayuki
    Ohtsu, Atsushi
    Mayer, Robert J.
    Winkler, Robert
    Amellal, Nadia
    Fougeray, Ronan
    Kanehisa, Akira
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [38] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
    Slamon, Dennis J.
    Neven, Patrick
    Chia, Stephen K. L.
    Jerusalem, Guy Heinrich Maria
    De laurentiis, Michelino
    Im, Seock-Ah
    Petrakova, Katarina
    Bianchi, Giulia Valeria
    Martin, Miguel
    Nusch, Arnd
    Sonke, Gabe S.
    de la Cruz-Merino, Luis
    Beck, J. Thaddeus
    Wang, Craig
    Deore, Uday
    Chakravartty, Arunava
    Zarate, Juan Pablo
    Taran, Tetiana
    Fasching, Peter A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [39] A multicenter analysis of the correlation between overall survival and progression-free survival and the number of chemotherapeutic key drugs used in patients with advanced/unresectable pancreatic cancer: Results from the NAPOLEON study
    Shirakawa, T.
    Ueda, Y.
    Shimokawa, M.
    Koga, F.
    Nakazawa, J.
    Komori, A.
    Arima, S.
    Fukahori, M.
    Makiyama, A.
    Taguchi, H.
    Honda, T.
    Uneda, S.
    Yoshida, M.
    Shibuki, T.
    Nio, K.
    Ide, Y.
    Ureshino, N.
    Mitsugi, K.
    Otsuka, T.
    ANNALS OF ONCOLOGY, 2020, 31 : S118 - S118
  • [40] Progression-free survival (PFS) and site of first progression in HER2+metastatic breast cancer (MBC) patients (pts) with (w) or without (w/o) brain metastases: A pooled analysis of tucatinib phase I studies
    Moulder, S.
    Hamilton, E.
    Ferrario, C.
    Conlin, A.
    Krop, I.
    Chamberlain, M.
    Gray, T.
    Borges, V.
    ANNALS OF ONCOLOGY, 2017, 28
12345